BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 25966772)

  • 1. Incidental thyroid C cell hyperplasia: clinical significance and implications in practice.
    Sakorafas GH; Nasikas D; Thanos D; Gantzoulas S
    Oncol Res Treat; 2015; 38(5):249-52. PubMed ID: 25966772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities.
    Perry A; Molberg K; Albores-Saavedra J
    Cancer; 1996 Feb; 77(4):750-6. PubMed ID: 8616768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ["Physiological" and "neoplastic" C-cell hyperplasia of the thyroid. Morphologically and biologically distinct entities?].
    Hinze R; Gimm O; Brauckhoff M; Schneyer U; Dralle H; Holzhausen HJ
    Pathologe; 2001 Jul; 22(4):259-65. PubMed ID: 11490939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients.
    Guyétant S; Josselin N; Savagner F; Rohmer V; Michalak S; Saint-André JP
    Mod Pathol; 2003 Aug; 16(8):756-63. PubMed ID: 12920219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma.
    Weinhaeusel A; Scheuba C; Lauss M; Kriegner A; Kaserer K; Vierlinger K; Haas OA; Niederle B
    Thyroid; 2008 Dec; 18(12):1269-76. PubMed ID: 18976163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-cell hyperplasia and medullary thyroid carcinoma in the rat. An immunohistochemical and ultrastructural analysis.
    DeLellis RA; Nunnemacher G; Bitman WR; Gagel RF; Tashjian AH; Blount M; Wolfe HJ
    Lab Invest; 1979 Feb; 40(2):140-54. PubMed ID: 431034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Non-neoplastic hypercalcitoninemia. Pathological anatomy].
    Saint-André JP; Guyétant S
    Ann Endocrinol (Paris); 1996; 57(1):23-6. PubMed ID: 8734285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels.
    Iacobone M; Niccoli-Sire P; Sebag F; De Micco C; Henry JF
    World J Surg; 2002 Aug; 26(8):886-90. PubMed ID: 12016469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia?
    Verga U; Ferrero S; Vicentini L; Brambilla T; Cirello V; Muzza M; Beck-Peccoz P; Fugazzola L
    Endocr Relat Cancer; 2007 Jun; 14(2):393-403. PubMed ID: 17639053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient affected by neurofibromatosis type 1 and thyroid C-cell hyperplasia harboring pathogenic germ-line mutations in both NF1 and RET genes.
    Ercolino T; Lai R; Giachè V; Melchionda S; Carella M; Delitala A; Mannelli M; Fanciulli G
    Gene; 2014 Feb; 536(2):332-5. PubMed ID: 24361808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of C-cell hyperplasia in patients with normal basal and pentagastrin-stimulated calcitonin.
    Scheuba C; Kaserer K; Kotzmann H; Bieglmayer C; Niederle B; Vierhapper H
    Thyroid; 2000 May; 10(5):413-6. PubMed ID: 10884188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of RET gene point mutations in sporadic thyroid C-cell hyperplasia.
    Saggiorato E; Rapa I; Garino F; Bussolati G; Orlandi F; Papotti M; Volante M
    J Mol Diagn; 2007 Apr; 9(2):214-9. PubMed ID: 17384213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-cell hyperplasia in sporadic and familial medullary thyroid carcinoma.
    Yadav M; Agrawal V; Pani KC; Verma R; Jaiswal S; Mishra A; Pandey R
    Indian J Pathol Microbiol; 2018; 61(4):485-488. PubMed ID: 30303134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Succinate dehydrogenase D variants do not constitute a risk factor for developing C cell hyperplasia or sporadic medullary thyroid carcinoma.
    Cascon A; Cebrian A; Pollan M; Ruiz-Llorente S; Montero-Conde C; Leton R; Gutierrez R; Lesueur F; Milne RL; Gonzalez-Albarran O; Lucas-Morante T; Benitez J; Ponder BA; Robledo M
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2127-30. PubMed ID: 15623805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels.
    Milone F; Ramundo V; Chiofalo MG; Severino R; Paciolla I; Pezzullo L; Lombardi G; Colao A; Faggiano A
    Clin Endocrinol (Oxf); 2010 Jul; 73(1):85-8. PubMed ID: 20039894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactive C cell hyperplasia as an incidental finding after thyroidectomy for papillary carcinoma.
    Manatakis DK; Bakavos A; Soulou VN; Dimakis C; Tseleni-Balafouta S
    Hormones (Athens); 2019 Sep; 18(3):289-295. PubMed ID: 31292912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial nonmultiple endocrine neoplasia medullary thyroid carcinoma: an evolving clinical entity.
    McHenry CR; Oppenheim DS; Murphy T; Broughan T; Vogt D; Goldfarb WB
    Surgery; 1992 Oct; 112(4):728-32; discussion 732-3. PubMed ID: 1411944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sporadic hypercalcitoninemia: clinical and therapeutic consequences.
    Scheuba C; Kaserer K; Moritz A; Drosten R; Vierhapper H; Bieglmayer C; Haas OA; Niederle B
    Endocr Relat Cancer; 2009 Mar; 16(1):243-53. PubMed ID: 18987170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.
    Learoyd DL; Gosnell J; Elston MS; Saurine TJ; Richardson AL; Delbridge LW; Aglen JV; Robinson BG
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):636-41. PubMed ID: 16343097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Basal and Calcium-stimulated Calcitonin Levels with Pathological Findings After Total Thyroidectomy.
    Papadakis G; Keramidas I; Triantafillou E; Kanouta F; Pappa T; Kaltzidou V; Tertipi A; Iordanidou L; Trivizaki E; Vecchini G; Villiotou V; Pappas A
    Anticancer Res; 2015 Jul; 35(7):4251-8. PubMed ID: 26124386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.